Mavrilimumab
(Anti-human GM-CSF mAb, human IgG1-Lambda2; KPL-301; CAM3001)
Catalog No.: PC-Ab1075Not For Human Use, Lab Use Only.
Mavrilimumab (KPL-301, CAM3001) is a monoclonal antibody to GM-CSF receptor-α chain, and competitive antagonist of GM-CSF signaling. Mavrilimumab also is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVI
Mavrilimumab (KPL-301, CAM3001) is a monoclonal antibody to GM-CSF receptor-α chain, and competitive antagonist of GM-CSF signaling. Mavrilimumab also is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Lambda2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
